My sensation is that it is too early to say ho well it works, but SE look pretty harsh!
The trial enrolled 181 men with mCRPC who had previously received one androgen receptor pathway inhibitor. Participants were randomized to receive vobramitamab at either 2.0 mg/kg or 2.7 mg/kg every four weeks. The primary endpoint was the six-month radiographic progression-free survival (rPFS) rate.
Results showed that both dosing regimens achieved similar six-month rPFS rates—69% for the 2.0 mg/kg group and 70% for the 2.7 mg/kg group. However, the higher dose of 2.7 mg/kg yielded a greater objective response rate among patients with measurable disease at baseline (41% vs. 20% in the 2.0 mg/kg group). PSA responses were comparable between the two doses.
Management of the Metastases in Oligometastatic Prostate Cancer 
Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant PC....anyone doing this one?
Xtandi monotherapy is very effective
